In this pooled analysis, median PFS was nearly 4 years and duration of response was nearly 4.5 years for those patients with relapsed/refractory MCL who achieved a CR with single agent ibrutinib therapy.
After a median follow-up of nearly 5 years, initial treatment with lenalidomide plus rituximab achieved a CR rate of 61%, with many patients in CR achieving MRD negativity.
In patients with R/R MCL, acalabrutinib monotherapy was associated with an ORR of 81% and ongoing responses at 12 months in 72% of these patients.
High patient baseline levels of tumor burden, LDH, and inflammatory biomarkers were associated with high levels of CAR T-cell expansion but increased rates of CRS and neurotoxicity.
The addition of polatuzumab vedotin to BR significantly increased ORR and CR rates in transplantation-ineligible patients with relapsed/refractory DLBCL vs BR alone.
A CR was achieved in 100% of patients with R/R HCL treated with the chemotherapy-free combination of vemurafenib plus rituximab.
Ibrutinib plus venetoclax for 6 months achieved deep responses with 1 in 3 patients attaining minimal residual disease–negative bone marrow.
In this interim analysis, venetoclax plus ibrutinib combination therapy achieved high response rates in patients with CLL, with many patients achieving MRD-negative bone marrow.
In patients with FL treated with BR induction therapy, 4 years vs 2 years of rituximab maintenance appears to improve PFS.
Tisagenlecleucel (CTL019) demonstrated an ORR of 53% with most CRs sustained at 6 months in patients with hard-to-treat relapsed/refractory DLBCL.
The chemotherapy-free combination of brentuximab vedotin plus nivolumab achieved a CR of 62% as first salvage therapy in patients with relapsed/refractory classical Hodgkin lymphoma without adverse effects on subsequent transplantation.
In patients with R/R cHL who continued nivolumab treatment following progression, 53% experienced reductions in tumor burden.
Brentuximab vedotin plus AVD reduced the risk of progression, death, or need for further anticancer therapy by 23% vs standard ABVD in patients with previously untreated advanced classical Hodgkin lymphoma.
In this expert analysis, John M. Burke, MD, and Christopher R. Flowers, MD, review and provide their perspective on key lymphomas and CLL studies presented at the Hematology 2017 annual meeting.
In a preplanned interim analysis of this phase III study, venetoclax plus rituximab significantly improved median PFS independent of del(17p) status vs bendamustine plus rituximab, with 60% of patients maintaining MRD negativity at 18 months.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.